Clinical Trial Update: Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination of an oncolytic adenovirus with pembrolizumab for brain cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Brain Neoplasm
• Glioblastoma
• Glioma
• Gliosarcoma
• Malignant Brain Tumor
• Neoplasm Neuroepithelial
• Neuroectodermal Tumors

Drugs mentioned

• Adenovirus (oncolytic agent from DNAtrix) (oncolytic adenovirus)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: DNAtrix, Inc. | Conditions: Brain Cancer, Brain Neoplasm | Phase 2 | Status: COMPLETED